MONTREAL--(BUSINESS WIRE)--June 5, 2006--Gemin X Biotechnologies, Inc. announced today that results from a Phase 1 clinical trial of GX15-070 in patients with refractory solid tumors and lymphomas showed the compound to be generally well-tolerated at doses resulting in biological activity. The findings were summarized in a poster presentation entitled “A Phase I Study of the Pan-Bcl2 Family Inhibitor GX15-070, Administered as a 3-hour Weekly Infusion in Patients with Refractory Solid Tumors or Lymphomas” (Abstract 3081; Kashif Alam Firozvi, et al.) during the American Society of Clinical Oncology (ASCO) 2006 Annual Meeting, June 2-6, 2006 in Atlanta, GA.
